Adjuvant radiotherapy outcome of stage i testicular seminoma: A single institution study

Hayoon Lee, Jun Won Kim, Sung Joon Hong, Seung Choul Yang, Young Deuk Choi, Koon Ho Rha, Jaeho Cho

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: To analyze treatment outcome and side effects of adjuvant radiotherapy using radiotherapy fields and doses which have evolved over the last two decades in a single institution. Materials and Methods: Forty-one patients received radiotherapy after orchiectomy from 1996 to 2007. At our institution, the treatment field for stage I seminoma has changed from dog-leg (DL) field prior to 2003 to paraaortic (PA) field after 2003. Fifteen patients were treated with the classic fractionation scheme of 25.5 Gy at 1.5 Gy per fraction. Other patients had been treated with modified schedules of 25.05 Gy at 1.67 Gy per fraction (n=15) and 25.2 Gy at 1.8 Gy per fraction (n=11). Results: With a median follow-up of 112 months, the 5-year and 10-year survival rates were 100% and 96%, respectively, and 5-year and 10-year relapse-free survival rates were both 97.1%. No in-field recurrence occurred. Contralateral seminoma occurred in one patient 5 years after treatment. No grade III‒IV acute toxicity occurred. An increased rate of grade 1‒2 acute hematologic toxicity was found in patients with longer overall treatment times due to 1.5 Gy per fraction. The rate of grade 2 acute gastrointestinal toxicity was significantly higher with DL field than with PA field and also higher in the 1.8-Gy group than in the 1.5-Gy and 1.67-Gy groups. Conclusion: Patients with stage I seminoma were safely treated with PA-only radiotherapy with no pelvic failure. Optimal fractionation schedule needs to be explored further in order to minimize treatment-related toxicity.

Original languageEnglish
Pages (from-to)24-30
Number of pages7
JournalYonsei medical journal
Volume56
Issue number1
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

Seminoma
Adjuvant Radiotherapy
Radiotherapy
Leg
Appointments and Schedules
Survival Rate
Dogs
Recurrence
Orchiectomy
Therapeutics

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Lee, Hayoon ; Kim, Jun Won ; Hong, Sung Joon ; Yang, Seung Choul ; Choi, Young Deuk ; Rha, Koon Ho ; Cho, Jaeho. / Adjuvant radiotherapy outcome of stage i testicular seminoma : A single institution study. In: Yonsei medical journal. 2015 ; Vol. 56, No. 1. pp. 24-30.
@article{07c07aeabafc495f958c36cbac34b526,
title = "Adjuvant radiotherapy outcome of stage i testicular seminoma: A single institution study",
abstract = "Purpose: To analyze treatment outcome and side effects of adjuvant radiotherapy using radiotherapy fields and doses which have evolved over the last two decades in a single institution. Materials and Methods: Forty-one patients received radiotherapy after orchiectomy from 1996 to 2007. At our institution, the treatment field for stage I seminoma has changed from dog-leg (DL) field prior to 2003 to paraaortic (PA) field after 2003. Fifteen patients were treated with the classic fractionation scheme of 25.5 Gy at 1.5 Gy per fraction. Other patients had been treated with modified schedules of 25.05 Gy at 1.67 Gy per fraction (n=15) and 25.2 Gy at 1.8 Gy per fraction (n=11). Results: With a median follow-up of 112 months, the 5-year and 10-year survival rates were 100{\%} and 96{\%}, respectively, and 5-year and 10-year relapse-free survival rates were both 97.1{\%}. No in-field recurrence occurred. Contralateral seminoma occurred in one patient 5 years after treatment. No grade III‒IV acute toxicity occurred. An increased rate of grade 1‒2 acute hematologic toxicity was found in patients with longer overall treatment times due to 1.5 Gy per fraction. The rate of grade 2 acute gastrointestinal toxicity was significantly higher with DL field than with PA field and also higher in the 1.8-Gy group than in the 1.5-Gy and 1.67-Gy groups. Conclusion: Patients with stage I seminoma were safely treated with PA-only radiotherapy with no pelvic failure. Optimal fractionation schedule needs to be explored further in order to minimize treatment-related toxicity.",
author = "Hayoon Lee and Kim, {Jun Won} and Hong, {Sung Joon} and Yang, {Seung Choul} and Choi, {Young Deuk} and Rha, {Koon Ho} and Jaeho Cho",
year = "2015",
month = "1",
day = "1",
doi = "10.3349/ymj.2015.56.1.24",
language = "English",
volume = "56",
pages = "24--30",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "1",

}

Adjuvant radiotherapy outcome of stage i testicular seminoma : A single institution study. / Lee, Hayoon; Kim, Jun Won; Hong, Sung Joon; Yang, Seung Choul; Choi, Young Deuk; Rha, Koon Ho; Cho, Jaeho.

In: Yonsei medical journal, Vol. 56, No. 1, 01.01.2015, p. 24-30.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Adjuvant radiotherapy outcome of stage i testicular seminoma

T2 - A single institution study

AU - Lee, Hayoon

AU - Kim, Jun Won

AU - Hong, Sung Joon

AU - Yang, Seung Choul

AU - Choi, Young Deuk

AU - Rha, Koon Ho

AU - Cho, Jaeho

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Purpose: To analyze treatment outcome and side effects of adjuvant radiotherapy using radiotherapy fields and doses which have evolved over the last two decades in a single institution. Materials and Methods: Forty-one patients received radiotherapy after orchiectomy from 1996 to 2007. At our institution, the treatment field for stage I seminoma has changed from dog-leg (DL) field prior to 2003 to paraaortic (PA) field after 2003. Fifteen patients were treated with the classic fractionation scheme of 25.5 Gy at 1.5 Gy per fraction. Other patients had been treated with modified schedules of 25.05 Gy at 1.67 Gy per fraction (n=15) and 25.2 Gy at 1.8 Gy per fraction (n=11). Results: With a median follow-up of 112 months, the 5-year and 10-year survival rates were 100% and 96%, respectively, and 5-year and 10-year relapse-free survival rates were both 97.1%. No in-field recurrence occurred. Contralateral seminoma occurred in one patient 5 years after treatment. No grade III‒IV acute toxicity occurred. An increased rate of grade 1‒2 acute hematologic toxicity was found in patients with longer overall treatment times due to 1.5 Gy per fraction. The rate of grade 2 acute gastrointestinal toxicity was significantly higher with DL field than with PA field and also higher in the 1.8-Gy group than in the 1.5-Gy and 1.67-Gy groups. Conclusion: Patients with stage I seminoma were safely treated with PA-only radiotherapy with no pelvic failure. Optimal fractionation schedule needs to be explored further in order to minimize treatment-related toxicity.

AB - Purpose: To analyze treatment outcome and side effects of adjuvant radiotherapy using radiotherapy fields and doses which have evolved over the last two decades in a single institution. Materials and Methods: Forty-one patients received radiotherapy after orchiectomy from 1996 to 2007. At our institution, the treatment field for stage I seminoma has changed from dog-leg (DL) field prior to 2003 to paraaortic (PA) field after 2003. Fifteen patients were treated with the classic fractionation scheme of 25.5 Gy at 1.5 Gy per fraction. Other patients had been treated with modified schedules of 25.05 Gy at 1.67 Gy per fraction (n=15) and 25.2 Gy at 1.8 Gy per fraction (n=11). Results: With a median follow-up of 112 months, the 5-year and 10-year survival rates were 100% and 96%, respectively, and 5-year and 10-year relapse-free survival rates were both 97.1%. No in-field recurrence occurred. Contralateral seminoma occurred in one patient 5 years after treatment. No grade III‒IV acute toxicity occurred. An increased rate of grade 1‒2 acute hematologic toxicity was found in patients with longer overall treatment times due to 1.5 Gy per fraction. The rate of grade 2 acute gastrointestinal toxicity was significantly higher with DL field than with PA field and also higher in the 1.8-Gy group than in the 1.5-Gy and 1.67-Gy groups. Conclusion: Patients with stage I seminoma were safely treated with PA-only radiotherapy with no pelvic failure. Optimal fractionation schedule needs to be explored further in order to minimize treatment-related toxicity.

UR - http://www.scopus.com/inward/record.url?scp=84918804356&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84918804356&partnerID=8YFLogxK

U2 - 10.3349/ymj.2015.56.1.24

DO - 10.3349/ymj.2015.56.1.24

M3 - Article

C2 - 25510743

AN - SCOPUS:84918804356

VL - 56

SP - 24

EP - 30

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - 1

ER -